Clinical Trial Update: A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity [Phase 2]

View source ↗

Summary

Phase 2 study evaluating LB54640 for genetic obesity shows ongoing investigation with unclear status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lepr Deficiency Obesity
• Pcsk1 Deficiency Obesity
• Pomc Deficiency Obesity

Drugs mentioned

• LB54640

Snippet

Sponsor: LG Chem | Conditions: POMC Deficiency Obesity, PCSK1 Deficiency Obesity | Phase 2 | Status: UNKNOWN